Category Archives: Newsletter

Volume 7, October 2019

How ADAPTABLE Study fits in the recent guidelines on use of aspirin in cardiovascular diseases

On March 17, 2019, the American College of Cardiology and the American Heart Association
jointly published recommendations based on recent studies on the use of aspirin to prevent cardiovascular diseases.

For individuals who have heart disease or had a heart attack or a stroke:
1. Aspirin should be used most of the times.
2. Aspirin is effective in reducing future heart problems.
3. We still don’t know the best dose of aspirin (81 mg or 325 mg per day).
4. The ADAPTABLE Study hopes to find the best dose of aspirin for patients who have a history of heart disease/heart attack or a stroke.

Read more from this newsletter.

Cómo se integra el estudio ADAPTABLE en los lineamientos recientes sobre el uso de la aspirina en las enfermedades cardiovasculares

El 17 de marzo de 2019, el Colegio Estadounidense de Cardiología y la Asociación Estadounidense del Corazón publicaron conjuntamente recomendaciones basadas
en estudios recientes sobre el uso de la aspirina para prevenir enfermedades cardiovasculares.

Para las personas que tienen enfermedad cardíaca o que han tenido un infarto o accidente cerebrovascular:

1. La aspirina se debe usar la mayoría de las veces.
2. La aspirina es eficaz para limitar la ocurrencia de futuros problemas cardíacos.
3. Todavía no sabemos cuál es la mejor dosis de aspirina (81 mg o 325 mg por día).
4. En el estudio ADAPTABLE, se espera encontrar la mejor dosis de aspirina para los pacientes que tienen antecedentes de enfermedad cardíaca/infarto o accidente cerebrovascular.

Lea más de este boletín.

Volume 6, February 2019

Top Lessons Learned from ADAPTABLE Patient Partners

ADAPTABLE patient partners, also known as Adaptors, provide input to the study team at every critical step in the research process. Adaptors are passionate about patient-centered research and draw on their personal work and life experiences to improve the study participant experience for current and future research participants. In this issue, we asked the Adaptors to share their top lessons learned from their experiences in ADAPTABLE.

Read more from this newsletter.

Lecciones fundamentales aprendidas por parte de los socios de los pacientes de ADAPTABLE

Los socios de los pacientes de ADAPTABLE, también
conocidos como adaptadores, proporcionan
información al equipo del estudio en cada paso crítico
en el proceso de investigación. A los adaptadores
les interesa mucho la investigación centrada en el
paciente y recurren a experiencias de su trabajo y
vida personal para mejorar la experiencia de los
participantes de estudios de investigación actuales y
futuros. En este asunto, les pedimos a los adaptadores
que compartan las lecciones fundamentales
aprendidas en ADAPTABLE.

Lea más de este boletín.

Volume 5, October/November 2018

Every Participant Counts from Enrollment to Study Completion

Equally important to enrollment of participants in a research study is retention. Retention is the number of patients who remain in the study until it is completed. Well-intentioned participants occasionally drop out early for a variety of reasons and, of course, they have this right. There is a fundamental principal that motivates researchers to retain participants in a study. Researchers and patients alike want to learn as much as possible from a study.

Read more about this Newsletter

Cada participante cuenta desde la inscripción hasta completar el estudio

Igualmente importante que la inscripción en un estudio de investigación es la retención. La retención es el número de pacientes que permanece en el estudio hasta que se completa. Los participantes con bien intencionados ocasionalmente se retiran antes por una serie de motivos y, por supuesto, tienen este derecho.

participateExiste un principio fundamental que motiva a los investigadores a retener participantes en un estudio. Tanto los investigadores como los pacientes desean aprender lo más posible sobre un studio.

Leer más sobre este boletín

Volume 4, May 2018


The Importance of Diversity in Clinical Research
Despite what is known about how certain groups of people may respond differently to disease; traditionally, the majority of cardiovascular clinical research study participants are white men. Increasing diversity in clinical research studies is a priority for the Food and Drug Administration and the ADAPTABLE team in making sure results provide evidence that is relevant and helpful to a wide range of people. Diversity in clinical research studies helps ensure that the results will have an impact on the people the study is intended to help.

VIEW NEWSLETTER FOR MAY 2018 (pdf)

 

SaveSave

SaveSave

Volume 3, February 2018

Celebrating Your Heart and Heart-Health Awareness & American Heart Month.
Heart disease is the leading cause of death for American women and men, responsible for one in four deaths in the U.S. According to the Centers for Disease Control and Prevention, someone in the U.S. has a heart attack every 40 seconds, and every year 790,000 Americans have a heart attack. For 210,000 people this is their second heart attack. Unfortunately, once you have had a heart attack, your chance of having another one increases. The good news is that there are actions you can take to protect your heart.

VIEW NEWSLETTER FOR February 2018 (pdf)

 

SaveSave

Volume 2, October 2017

Better health outcomes for all when patients partner with researchers.
This motto crafted by the Adaptors, ADAPTABLE’s patient partners, reflects how patient participation in research can help answer health questions that matter most to patients and their doctors. The Adaptors’ motto is part of the Hero’s Journey Art Project, a touring art exhibit developed by Eli Lilly to honor clinical trial participants and raise awareness of clinical research.

VIEW NEWSLETTER FOR October 2017 (pdf)

 

Volume 1: Welcome, June 2017

Thank you for your participation in the ADAPTABLE Study.

Your involvement in this research study will help us to answer a simple, but extremely important question—what is the best aspirin dose (81 mg or 325 mg) for patients with heart disease? In addition to answering the aspirin-dose question, ADAPTABLE is building a community where patients are partners throughout the research process.

 

VIEW NEWSLETTER FOR June 2017 (pdf)

tertiary sidebar container